Rep. Lisa C. McClain Sells Off Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

Representative Lisa C. McClain (R-Michigan) recently sold shares of Roivant Sciences Ltd. (NASDAQ:ROIV). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in Roivant Sciences stock on October 30th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

Roivant Sciences Trading Up 0.0%

ROIV traded up $0.01 during trading on Thursday, hitting $20.87. 4,846,723 shares of the company traded hands, compared to its average volume of 8,455,984. The company has a market cap of $14.51 billion, a PE ratio of -37.27 and a beta of 1.23. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $21.35. The stock’s 50-day simple moving average is $18.15 and its two-hundred day simple moving average is $13.91.

Institutional Trading of Roivant Sciences

Several large investors have recently made changes to their positions in the business. Bessemer Group Inc. grew its position in Roivant Sciences by 41.5% during the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after buying an additional 543 shares during the period. Utah Retirement Systems lifted its position in Roivant Sciences by 3.0% during the third quarter. Utah Retirement Systems now owns 20,626 shares of the company’s stock worth $312,000 after buying an additional 600 shares in the last quarter. Xponance Inc. increased its position in Roivant Sciences by 1.9% during the third quarter. Xponance Inc. now owns 46,718 shares of the company’s stock worth $707,000 after purchasing an additional 882 shares during the last quarter. CWM LLC grew its position in Roivant Sciences by 44.6% in the second quarter. CWM LLC now owns 2,984 shares of the company’s stock worth $34,000 after acquiring an additional 920 shares during the period. Finally, Oregon Public Employees Retirement Fund lifted its position in Roivant Sciences by 1.2% in the third quarter. Oregon Public Employees Retirement Fund now owns 86,652 shares of the company’s stock valued at $1,311,000 after buying an additional 1,019 shares during the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ROIV has been the topic of several recent research reports. HC Wainwright upped their price objective on Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday, September 18th. JPMorgan Chase & Co. increased their price target on shares of Roivant Sciences from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Thursday, September 18th. Jefferies Financial Group lifted their price target on Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, September 18th. Wall Street Zen upgraded Roivant Sciences from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. Finally, Weiss Ratings upgraded Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a report on Saturday, October 25th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $22.56.

Insiders Place Their Bets

In other news, major shareholder Vivek Ramaswamy sold 1,195,000 shares of Roivant Sciences stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $12.50, for a total value of $14,937,500.00. Following the completion of the sale, the insider directly owned 36,089,108 shares of the company’s stock, valued at approximately $451,113,850. The trade was a 3.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Eric Venker sold 683,818 shares of Roivant Sciences stock in a transaction dated Friday, September 19th. The shares were sold at an average price of $14.95, for a total value of $10,223,079.10. Following the completion of the transaction, the chief executive officer directly owned 1,969,767 shares of the company’s stock, valued at approximately $29,448,016.65. This represents a 25.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 8,483,561 shares of company stock worth $143,557,750 over the last ninety days. Corporate insiders own 10.80% of the company’s stock.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.